Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:BBIO NASDAQ:GMAB NASDAQ:KNSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$264.11+1.7%$242.44$160.86▼$282.15$16.47B0.37713,246 shs384,190 shsBBIOBridgeBio Pharma$81.66+1.7%$70.85$42.09▼$93.42$15.98B0.953.12 million shs659,486 shsGMABGenmab A/S$28.64-1.2%$26.57$21.00▼$35.43$17.87B0.841.84 million shs1.44 million shsKNSAKiniksa Pharmaceuticals International$64.32+5.2%$56.32$26.27▼$67.53$4.94B0.07720,181 shs436,722 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-3.27%-5.67%+12.37%+6.27%+48.12%BBIOBridgeBio Pharma-2.86%-10.95%+20.50%+4.63%+70.49%GMABGenmab A/S-0.34%-2.69%+17.14%+1.51%+32.51%KNSAKiniksa Pharmaceuticals International-0.94%-6.53%+16.85%+36.10%+115.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$264.11+1.7%$242.44$160.86▼$282.15$16.47B0.37713,246 shs384,190 shsBBIOBridgeBio Pharma$81.66+1.7%$70.85$42.09▼$93.42$15.98B0.953.12 million shs659,486 shsGMABGenmab A/S$28.64-1.2%$26.57$21.00▼$35.43$17.87B0.841.84 million shs1.44 million shsKNSAKiniksa Pharmaceuticals International$64.32+5.2%$56.32$26.27▼$67.53$4.94B0.07720,181 shs436,722 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-3.27%-5.67%+12.37%+6.27%+48.12%BBIOBridgeBio Pharma-2.86%-10.95%+20.50%+4.63%+70.49%GMABGenmab A/S-0.34%-2.69%+17.14%+1.51%+32.51%KNSAKiniksa Pharmaceuticals International-0.94%-6.53%+16.85%+36.10%+115.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.05Buy$295.6711.95% UpsideBBIOBridgeBio Pharma 2.83Moderate Buy$95.2116.60% UpsideGMABGenmab A/S 2.75Moderate Buy$38.2133.43% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$65.141.29% UpsideCurrent Analyst Ratings BreakdownLatest KNSA, GMAB, ASND, and BBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2026BBIOBridgeBio Pharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$82.00 ➝ $93.007/15/2026ASNDAscendis Pharma A/S Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Hold (C)7/13/2026BBIOBridgeBio Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$110.00 ➝ $120.007/13/2026KNSAKiniksa Pharmaceuticals International Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$57.00 ➝ $74.007/7/2026ASNDAscendis Pharma A/S Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$275.00 ➝ $280.007/2/2026GMABGenmab A/S HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $40.006/29/2026KNSAKiniksa Pharmaceuticals International WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$59.00 ➝ $72.006/23/2026KNSAKiniksa Pharmaceuticals International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)6/23/2026GMABGenmab A/S HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.006/17/2026KNSAKiniksa Pharmaceuticals International Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/16/2026BBIOBridgeBio Pharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$106.00 ➝ $96.00(Data available from 7/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$814.57M20.23N/AN/A($2.97) per share-88.93BBIOBridgeBio Pharma$502.08M31.85N/AN/A($10.77) per share-7.58GMABGenmab A/S$3.72B4.80$1.59 per share18.07$9.10 per share3.15KNSAKiniksa Pharmaceuticals International$677.56M7.30$0.83 per share77.72$7.44 per share8.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$258M$8.6730.4521.76N/A57.87%N/A-8.37%8/6/2026 (Estimated)BBIOBridgeBio Pharma-$724.93M-$3.74N/A510.36N/A-124.42%N/A-65.81%8/4/2026 (Estimated)GMABGenmab A/S$963M$1.3221.7218.011.8521.05%15.34%8.94%8/6/2026 (Estimated)KNSAKiniksa Pharmaceuticals International$59.01M$0.9071.3536.54N/A9.69%13.26%9.86%7/28/2026 (Estimated)Latest KNSA, GMAB, ASND, and BBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026ASNDAscendis Pharma A/S$1.27N/AN/AN/A$438.35 millionN/A8/6/2026Q2 2026GMABGenmab A/S$0.35N/AN/AN/A$1.10 billionN/A8/4/2026Q2 2026BBIOBridgeBio Pharma-$0.64N/AN/AN/A$220.45 millionN/A7/28/2026Q2 2026KNSAKiniksa Pharmaceuticals International$0.30N/AN/AN/A$226.49 millionN/A5/7/2026Q1 2026ASNDAscendis Pharma A/S$0.21$0.32+$0.11$11.29$362.47 million$285.45 million5/7/2026Q1 2026BBIOBridgeBio Pharma-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 million4/28/2026Q1 2026KNSAKiniksa Pharmaceuticals International$0.18$0.27+$0.09$0.27$206.11 million$214.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/AGMABGenmab A/SN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/S0.791.000.72BBIOBridgeBio PharmaN/A1.521.48GMABGenmab A/S0.872.182.17KNSAKiniksa Pharmaceuticals InternationalN/A3.793.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ABBIOBridgeBio Pharma99.85%GMABGenmab A/S7.07%KNSAKiniksa Pharmaceuticals International53.95%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%BBIOBridgeBio Pharma14.23%GMABGenmab A/S1.54%KNSAKiniksa Pharmaceuticals International51.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableBBIOBridgeBio Pharma400195.86 million167.99 millionOptionableGMABGenmab A/S3,029623.53 million613.93 millionOptionableKNSAKiniksa Pharmaceuticals International22076.94 million36.95 millionOptionableKNSA, GMAB, ASND, and BBIO HeadlinesRecent News About These CompaniesBrokerages Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Target Price at $62.71July 17 at 5:15 AM | americanbankingnews.comKiniksa Pharmaceuticals: Leader In Pericarditis Merits Hold Rating After Recent GainsJuly 15 at 11:08 AM | seekingalpha.com4 Top-Ranked Stocks With Solid Net Profit Margins to Boost Your GainsJuly 14 at 10:20 AM | zacks.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price Expected to Rise, Wells Fargo & Company Analyst SaysJuly 13, 2026 | marketbeat.comKiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Buy" from AnalystsJuly 12, 2026 | marketbeat.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Rating Lowered to Buy at Wall Street ZenJuly 12, 2026 | marketbeat.comKiniksa Pharmaceuticals International (KNSA) Joins Russell Indexes, Is The Upside Already Priced In?July 9, 2026 | finance.yahoo.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 12-Month High - Here's What HappenedJuly 6, 2026 | marketbeat.comKiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's WhyJuly 6, 2026 | zacks.comPeregrine Capital Management LLC Sells 29,550 Shares of Kiniksa Pharmaceuticals International, plc $KNSAJuly 1, 2026 | marketbeat.comInspire Investing LLC Makes New $1.70 Million Investment in Kiniksa Pharmaceuticals International, plc $KNSAJuly 1, 2026 | marketbeat.comPictet Asset Management Holding SA Sells 164,232 Shares of Kiniksa Pharmaceuticals International, plc $KNSAJuly 1, 2026 | marketbeat.comWhat Makes Kiniksa Pharmaceuticals International, plc (KNSA) a Strong Momentum Stock: Buy Now?June 30, 2026 | zacks.comKiniksa Pharmaceuticals International, plc (KNSA) Surges 5.4%: Is This an Indication of Further Gains?June 30, 2026 | zacks.comAMI Asset Management Corp Has $1.06 Million Stake in Kiniksa Pharmaceuticals International, plc $KNSAJune 30, 2026 | marketbeat.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 12-Month High on Analyst UpgradeJune 29, 2026 | marketbeat.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $72.00June 29, 2026 | marketbeat.comGrab These 4 Stocks With Solid Net Profit Margins to Maximize ReturnsJune 29, 2026 | zacks.comHere's Why You Should Add Kiniksa Stock to Your Portfolio NowJune 26, 2026 | zacks.comKiniksa Pharmaceuticals International, plc $KNSA Shares Bought by SG Americas Securities LLCJune 24, 2026 | marketbeat.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 52-Week High - Time to Buy?June 23, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKNSA, GMAB, ASND, and BBIO Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$264.11 +4.31 (+1.66%) As of 03:12 PM Eastern This is a fair market value price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.BridgeBio Pharma NASDAQ:BBIO$81.66 +1.36 (+1.69%) As of 03:12 PM Eastern This is a fair market value price provided by Massive. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Genmab A/S NASDAQ:GMAB$28.64 -0.34 (-1.17%) As of 03:12 PM Eastern This is a fair market value price provided by Massive. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Kiniksa Pharmaceuticals International NASDAQ:KNSA$64.32 +3.21 (+5.24%) As of 03:12 PM Eastern This is a fair market value price provided by Massive. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector GE Aerospace Faces a Prove-It Moment in Q2 Earnings Sandisk: What the Chart Is Trying to Tell Us Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Has Broadcom Become Too Expensive for Its AI Story? 3 Picks-and-Shovels Stocks Powering the Humanoid Robotics Buildout Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
